Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 23:00:00 11/07/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.96%

03-25	North American Morning Briefing : Tech in Focus on -2-	DJ
03-25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI

Infinity Pharmaceuticals, Inc. Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium

January 11, 2021 at 01:05 pm

Infinity Pharmaceuticals, Inc. will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021. MARIO-275 is a randomized, placebo- controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced urothelial cancer over nivolumab monotherapy, which is approved in this setting.

Latest news about Infinity Pharmaceuticals, Inc.

North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Infinity Pharmaceuticals, Inc. Went Out of Business	03-25	CI
Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	03-07	CI
Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc.	02-22	CI
An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	02-14	CI
First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc.	02-13	CI
Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc.	02-01	CI
First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc.	01-26	CI
North American Morning Briefing : Tech Likely to -2-	01-19	DJ
North American Morning Briefing : Stock Futures Waver Ahead of Bank-Earnings Bonanza	01-12	DJ
Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc.	01-11	CI
Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc.	01-08	CI
North American Morning Briefing : Bond Yields Rise -2-	01-05	DJ
North American Morning Briefing : Stock Futures Gain as 2023 Draws to a Close	12-29	DJ
North American Morning Briefing : Stock Futures -2-	12-18	DJ
North American Morning Briefing : Investors Await -2-	12-11	DJ
North American Morning Briefing : Stock Futures, -2-	12-04	DJ
North American Morning Briefing : Stock Futures -2-	11-27	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	11-20	DJ
North American Morning Briefing : Stock Futures -2-	11-13	DJ
Bidding Procedure Approved for Infinity Pharmaceuticals, Inc.	23/10/23	CI
Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc.	02/10/23	CI
Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board	29/09/23	CI
INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI…	29/09/23	RE
Motion for Asset Sale Filed by Infinity Pharmaceuticals, Inc.	29/09/23	CI

Chart Infinity Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
INFINITY PHARMACEUTICALS, INC.	-99.96%	90
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research